Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPPL2A | Q8TCT8 | 15/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SCD | O00767 | 1/20 | 0.35 |
| ▸ | XIAP | P98170 | 1/20 | 0.35 |
| ▸ | ACACB | O00763 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25409651 | 1.00 | SPPL2A (1.00) | SPPL2ACYP1A2GAACYP2C9RXFP1 | |
| SCHEMBL25409772 | 0.91 | SPPL2A (1.00) | SPPL2ACYP1A2GAACYP2C9RXFP1 | |
| SCHEMBL25409768 | 0.91 | SPPL2A (1.00) | SPPL2ACYP1A2GAACYP2C9RXFP1 | |
| SCHEMBL26686997 | 0.90 | SPPL2A (0.82) | SPPL2AHTTXIAP | |
| SCHEMBL30617041 | 0.89 | SPPL2A (0.80) | SPPL2AXIAP | |
| SCHEMBL31675943 | 0.88 | SPPL2A (0.79) | SPPL2AXIAP | |
| SCHEMBL26853473 | 0.88 | SPPL2A (0.79) | SPPL2AXIAP | |
| SCHEMBL26848152 | 0.87 | SPPL2A (0.78) | SPPL2AXIAP | |
| SCHEMBL25407286 | 0.87 | SPPL2A (0.77) | SPPL2ASCD | |
| SCHEMBL25407284 | 0.87 | SPPL2A (0.77) | SPPL2ASCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4214210-B1 | COMPOUNDS AND COMPOSITIONS AS SPPL2A INHIBITORS | NOVARTIS AG (CH) | 2025-04-09 | — | — | EP | claimed |
| US-20230365571-A1 | COMPOUNDS AND COMPOSITIONS AS Sppl2a INHIBITORS | NOVARTIS AG (CH) | 2023-11-16 | — | — | US | claimed |
| EP-4214210-A1 | COMPOUNDS AND COMPOSITIONS AS SPPL2A INHIBITORS | Novartis AG (CH) | 2023-07-26 | — | — | EP | claimed |
| EP-4578451-A2 | COMPOUNDS AND COMPOSITIONS AS SPPL2A INHIBITORS | Novartis AG (CH) | 2025-07-02 | — | — | EP | disclosed |
| EP-4214210-B1 | COMPOUNDS AND COMPOSITIONS AS SPPL2A INHIBITORS | NOVARTIS AG (CH) | 2025-04-09 | — | — | EP | disclosed |
| US-20230365571-A1 | COMPOUNDS AND COMPOSITIONS AS Sppl2a INHIBITORS | NOVARTIS AG (CH) | 2023-11-16 | — | — | US | disclosed |
| EP-4214210-A1 | COMPOUNDS AND COMPOSITIONS AS SPPL2A INHIBITORS | Novartis AG (CH) | 2023-07-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365571-A1 | COMPOUNDS AND COMPOSITIONS AS Sppl2a INHIBITORS | SPPL2A, SPPL2B, BACE1 | SPPL2A 1/4885CYP1A2 3074/4885GAA 2507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.